Andrew Reardon - 01 Nov 2022 Form 3 Insider Report for LIGAND PHARMACEUTICALS INC (LGND)

Role: Chief Legal Officer and Secretary Exhibit 24 - Power of Attorney.
Signature: /s/ Andrew Reardon
Issuer symbol: LGND
Transactions as of: 01 Nov 2022
Net transactions value: $0
Form type: 3
Filing time: 07 Nov 2022, 19:23:52 UTC
Next filing: 01 Dec 2022
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
holding	LGND	Common Stock						12,013	01 Nov 2022	Direct	F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
holding	LGND	Employee Stock Option (right to buy)							01 Nov 2022	Common Stock	72,944	$52.27	Direct	F2

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Includes 8,581 restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of the Issuer's Common Stock and does not expire.
F2	The stock option vests and is exercisable as to 12.5% of the underlying shares on February 1, 2023, and in 42 substantially equal monthly installments thereafter.

Remarks:

Chief Legal Officer and Secretary Exhibit 24 - Power of Attorney.